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Background
Europe is seeing more non-B subtype HIV, reflecting pat-
terns of migration. In France in 2003, 19% of new infec-
tions were non-B subtype [1] and UK data showed a rise
in infection acquired heterosexually in Africa: 19% in
1992, to 33% in 2006 [2]. With the roll-out of antiretrovi-
rals (ART) in the developing world and use of single dose
nevirapine for prevention of mother-to-child transmis-
sion, reports of emerging transmitted drug resistance
(TDR) among non-B subtypes have followed.
Methods
We describe trends in resistance testing and TDR in the UK
with a focus on non-B subtypes, using resistance tests
reported to the UK HIV drug resistance database up to
end-2006. First tests from ART-naïve individuals were
included. Tests performed pre-2001 were excluded to
minimise testing selection bias. TDR was defined as the
presence of ≥1 mutation on Shafer's list 2007. Demo-
graphic data were acquired from UK CHIC. Logistic
regression was used to examine associations between sub-
type, demographics and prevalence of TDR.
Summary of results
The number of tests done on non-B subtypes has
increased: from 25% in 2001, to 50% in 2006; 10,687
resistance tests were included in our analysis, 4,643 were
from individuals infected with non-B subtypes. Overall,
230/4,643 (5%) samples with non-B subtypes showed
TDR compared to 660/6,022 (11%) with subtype B (p <
0.001), with TDR decreasing over time in both groups
(Figure 1). Multivariate analysis revealed a more rapid
decrease for non-B subtype (OR = 0.62 per year, 95% CI
0.46–0.84, p = 0.002) than subtype B (OR 0.95 per year,
95% CI 0.90–1.00, p = 0.04); this interaction is highly sig-
nificant (p = 0.009). Overall, 82% of individuals with
TDR had resistance to one drug class only, 13% and 5% to
two and three classes, respectively. This pattern was simi-
lar in B and non-B subtypes. Within each drug class, TDR
was significantly less likely among non-B subtypes,
although the difference was smaller in the NNRTI class (p
= 0.03).
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Prevalence of TDR in subtype B vs non-B virusFigur  1
Prevalence of TDR in subtype B vs non-B virus.Page 1 of 2
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These data suggest that TDR is significantly lower amongst
non-B subtypes, with the presence of TDR decreasing
more rapidly over calendar year in this group. However,
we cannot exclude testing bias, especially in earlier years.
Reassuringly, TDR is mainly confined to one drug class.
Despite the widespread use of NNRTI in the developing
world, NNRTI resistance remains significantly lower in
non-B subtypes. There is a proportional increase in the
resistance tests done in naïve individuals with non-B sub-
types, reflecting guidelines.
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